Sangamo Therapeutics Statistics
Total Valuation
SGMO has a market cap or net worth of $149.64 million. The enterprise value is $145.45 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SGMO has 336.49 million shares outstanding. The number of shares has increased by 28.25% in one year.
| Current Share Class | 336.49M |
| Shares Outstanding | 336.49M |
| Shares Change (YoY) | +28.25% |
| Shares Change (QoQ) | +18.42% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 18.38% |
| Float | 329.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.36 |
| Forward PS | 1.88 |
| PB Ratio | 22.94 |
| P/TBV Ratio | 23.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 4.07.
| Current Ratio | 0.88 |
| Quick Ratio | 0.69 |
| Debt / Equity | 4.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -480.02% and return on invested capital (ROIC) is -138.19%.
| Return on Equity (ROE) | -480.02% |
| Return on Assets (ROA) | -68.11% |
| Return on Invested Capital (ROIC) | -138.19% |
| Return on Capital Employed (ROCE) | -282.79% |
| Revenue Per Employee | $179,645 |
| Profits Per Employee | -$595,131 |
| Employee Count | 183 |
| Asset Turnover | 0.33 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -442,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.77% in the last 52 weeks. The beta is 1.40, so SGMO's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -81.77% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 30.98 |
| Average Volume (20 Days) | 4,608,325 |
Short Selling Information
The latest short interest is 14.19 million, so 4.22% of the outstanding shares have been sold short.
| Short Interest | 14.19M |
| Short Previous Month | 17.12M |
| Short % of Shares Out | 4.22% |
| Short % of Float | 4.31% |
| Short Ratio (days to cover) | 3.09 |
Income Statement
In the last 12 months, SGMO had revenue of $32.88 million and -$108.91 million in losses. Loss per share was -$0.44.
| Revenue | 32.88M |
| Gross Profit | -72.03M |
| Operating Income | -108.93M |
| Pretax Income | -109.35M |
| Net Income | -108.91M |
| EBITDA | -104.68M |
| EBIT | -108.93M |
| Loss Per Share | -$0.44 |
Full Income StatementBalance Sheet
The company has $29.62 million in cash and $25.42 million in debt, giving a net cash position of $4.19 million or $0.01 per share.
| Cash & Cash Equivalents | 29.62M |
| Total Debt | 25.42M |
| Net Cash | 4.19M |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 6.24M |
| Book Value Per Share | 0.02 |
| Working Capital | -6.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$76.16 million and capital expenditures -$240,000, giving a free cash flow of -$76.40 million.
| Operating Cash Flow | -76.16M |
| Capital Expenditures | -240,000 |
| Free Cash Flow | -76.40M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
| Gross Margin | -219.11% |
| Operating Margin | -331.33% |
| Pretax Margin | -332.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.25% |
| Shareholder Yield | -28.25% |
| Earnings Yield | -72.78% |
| FCF Yield | -51.05% |
Analyst Forecast
The average price target for SGMO is $4.71, which is 959.14% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.71 |
| Price Target Difference | 959.14% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 40.14% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SGMO has an Altman Z-Score of -27.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.24 |
| Piotroski F-Score | 2 |
